A new angle for glp-1 receptor agonist: the medical economics argument Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print

Journal of Medical Economics
Willy Marcos Valencia, Hermes Jose Florez

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are relatively new medications for diabetes that offer a weight-loss profile that can be considered desirable for patients with both type 2 diabetes (T2D) and obesity. GLP-1 RA are effective in combination with insulin, and even slightly superior or at least equal to short-acting insulin in T2D; however, since they work in the incretin system, they may not be effective in long-standing disease. Additionally, only recently have publications reported their cardiovascular safety, and there is limited evidence for long-term effectiveness. The work presented by Huetson et al. offers a much needed perspective through a medical economic model for the long term cost-effectiveness of GLP-1 RA. The authors found benefits in quality-adjusted life years and reduced lifetime healthcare costs. While there are a few limitations, this study contributes to the understanding of these agents and their impact on the epidemics of obesity in T2D, where weight management is no longer an option, but an essential component of the diabetes plan of care.

References

Sep 5, 2008·PharmacoEconomics·Christopher McCabeAnthony J Culyer
Feb 23, 2010·Diabetes Research and Clinical Practice·Ping ZhangGregory Nichols
Oct 19, 2011·Journal of General Internal Medicine·Quyen Ngo-MetzgerSherrie H Kaplan
Jul 31, 2014·Diabetes, Obesity & Metabolism·W M Valencia, H Florez
Oct 6, 2014·The American Journal of Medicine·Steven Edelman, Jeremy Pettus
Mar 22, 2015·Journal of Diabetes and Its Complications·Yeganeh Manon KhazraiPaolo Pozzilli
Apr 11, 2015·Clinical Medicine Insights. Endocrinology and Diabetes·Andreas LieblJean-Francois Yale
Apr 17, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberMichael H Davidson
May 23, 2015·Diabetes Care·Luc Van Gaal, André Scheen
Jun 10, 2015·Journal of Medical Economics·W SuL Perreault

❮ Previous
Next ❯

Citations

Sep 27, 2016·Atencion primaria·M Mar Roca-RodríguezIsabel Mancha-Doblas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Ivana BabovićRadmila Sparić
© 2021 Meta ULC. All rights reserved